A5102752608- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Drug-Induced Adverse Reactions
- Chronic Lymphocytic Leukemia Research
- Chemotherapy-related skin toxicity
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Cancer survivorship and care
- Advanced Breast Cancer Therapies
- Melanoma and MAPK Pathways
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Blood disorders and treatments
- Tuberous Sclerosis Complex Research
- Multiple and Secondary Primary Cancers
- CNS Lymphoma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Immune Cell Function and Interaction
- Autoimmune Bullous Skin Diseases
- Polyomavirus and related diseases
- Autoimmune Neurological Disorders and Treatments
Fred Hutch Cancer Center
2022-2025
University of Washington
2022-2025
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2024
University Hospitals Seidman Cancer Center
2017-2022
Case Western Reserve University
2019-2021
University Hospitals of Cleveland
2020
Temple University Hospital
2018
Fox Chase Cancer Center
2017
Rawalpindi Medical University
2012
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted multicenter retrospective cohort analysis of patients treated venetoclax to describe outcomes, toxicities, and treatment selection discontinuation. A total 141 were included (98% relapsed/refractory). Median age at initiation was 67 years (range 37-91), median prior therapies 3 (0-11), 81% unmutated IGHV, 45% del(17p), 26.8% complex...
Heparin resistance can be defined as high doses of unfractionated heparin (UFH), greater than 35,000 IU/day, required to raise the activated partial thromboplastin time (aPTT) and coagulation (ACT) within therapeutically desired ranges or impossibility doing so. The most common pathology responsible is deficiency anti-thrombin III (ATIII) deficiency. Other clinically relevant conditions that present with are congenital deficiencies; use during extracorporeal circulation, asparaginase therapy...
Multiparameter flow cytometry (MFC) measurable residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) independently predicts poor outcomes in acute myeloid leukemia (AML). Conversely, its prognostic value the newly defined entity, myelodysplastic neoplasm (MDS)/AML is unknown. To assess relationship between type, pre-HCT MRD, and post-HCT outcomes, we retrospectively analyzed 1265 adults with MDS/AML (n = 151) or AML 1114) who received a first allograft second...
Azacitidine (AZA) maintenance following allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) may reduce relapse risk improve survival. Given logistic toxicity-related challenges, identifying subgroups appropriate this approach is an unmet need. Using data from two centers, we retrospectively compared event-free survival (EFS) overall (OS) of AML MDS patients who received AZA (n = 59) with historic controls 90). Controls were...
Lenalidomide (LEN) is commonly used as part of induction therapy in transplant-eligible patients with multiple myeloma. However, LEN use associated increased chance peripheral blood stem cell (PBSC) collection failure. This has led to early receiving LEN-containing regimens, and the mobilization agents such plerixafor. Despite potential significant clinical implications, impact on autograft composition unclear. We examined effect exposure hematopoietic progenitors collected grafts 94 who...
Patients undergoing hematopoietic cell transplantation (HCT) experience decline in their physical activity during transplant admission. There is limited with prospective monitoring of recipients. We therefore measured and sleep patterns subjects autologous allogeneic HCT. Eighty-three patients were consented for this study. Sixty-three competed the study had prospectively assessed using fitness-tracking device Fitbit HR. Outcomes included adherence, activity, readmission, engraftment,...
Paraneoplastic syndromes are commonly encountered in renal cell carcinoma, but neurological manifestations rare. Herein we report a case of patient with locally advanced carcinoma who presented Parkinson-like symptoms which prohibited surgery due to poor performance status. However, significant improvement was noted after tyrosine kinase inhibitor therapy, allowing the proceed curative surgery.
Background There is limited information on the activity patterns of patients undergoing HSCT and their effect transplant related outcomes, functional recovery length hospital stay. We conducted a prospective study to determine feasibility using fitness tracking device in HSCT. Methods Patients were consented wear (Fitbit®). Parameters measured include steps, distance, active calories, heart rate. Comparisons between groups done Mann-Whitney test Fisher's exact test; correlations evaluated...
Reduced-intensity conditioning (RIC) regimens frequently provide insufficient disease control in patients with high-risk hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated intensification of fludarabine/busulfan (Flu/Bu) RIC targeted marrow irradiation (TMI) a dose escalation expansion phase I clinical trial. TMI doses were delivered at 1.5 Gy twice daily fractions on days -10 through -7 (dose levels: 3 Gy, 4.5 and 6 Gy), Flu (30 mg/m2...
Methodological advancements now allow older adults with AML to receive allografts although conflicting data exist regarding relative outcomes across age groups and benefits of different conditioning intensities. We retrospectively analyzed 495 aged 60-64 (n = 184), 65-69 189), or ≥ 70 122) who underwent allogeneic HCT for in remission at our institution from 2006 2023. There were no significant differences relapse relapse-free survival (RFS) among the 3 cohorts after multivariable...
Background: Central venous access is indispensable for patients undergoing hematopoietic stem cell transplantation administration of chemotherapy drugs, cells, antimicrobials and blood products. However, central-line associated bloodstream infections (CLABSI) cause significant morbidity mortality in this subset immunocompromised patients. This study was conducted to evaluate the risk CLABSI with use different types central-lines used at out institution. Methods: All consecutive from January...